ライフサイエンスコーパス: lactamase

1 ked to catalytic activity of the CTX-M9 beta lactamase.

2 d not inhibit unfolding of the inserted beta-lactamase.

3 n an important antibiotic target--TEM-1 beta-lactamase.

4 single sites randomly throughout TEM-1 beta-lactamase.

5 ng an AmpC and 11 coproducing a metallo-beta-lactamase.

6 tection of the beta-lactam, of the AmpC beta-lactamase.

7 for the beta-lactam resistance enzyme, beta-lactamase.

8 9) of which expressed extended-spectrum beta-lactamase.

9 tor was unlikely to have been a metallo-beta-lactamase.

10 or BlaC over TEM-1 Bla, the most common beta-lactamase.

11 neumoniae carbapenemase (KPC-2) class A beta-lactamase.

12 isolates coproducing an AmpC or metallo-beta-lactamase.

13 % of isolates that coproduced a metallo-beta-lactamase.

14 (ESBLs), AmpCs, K1, and broad-spectrum beta-lactamases.

15 philic serine enzymes, including serine-beta-lactamases.

16 ta-lactamases such as New Delhi metallo-beta-lactamases.

17 apenemase activity of the GES family of beta-lactamases.

18 iae carbapenemases (KPC) and additional beta-lactamases.

19 sitive detection of clinically-relevant beta-lactamases.

20 substituted in the mechanism of serine beta-lactamases.

21 ing into the active sites of key serine beta-lactamases.

22 t of resident soil bacteria that harbor beta-lactamases.

23 pectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

24 d inhibitors of serine and some metallo beta-lactamases.

25 istance, specifically New Delhi metallo-beta-lactamase-1 (NDM-1).

26 ant E. coli harboring New Delhi metallo-beta-lactamase-1.

27 ffects of all single mutations in TEM-1 beta-lactamase (4,997 variants) under selection for the wild-

28 oniae carbapenemase (56.1%), 54 metallo-beta-lactamase (40.9%), and four both (3.0%).

29 gE is a T3SS effector by two methods, a beta-lactamase activity assay and a split green fluorescent p

30 Metallo-beta-lactamase activity is thought to be polyphyletic, having

31 f the TEM-1, TEM-17, TEM-19, and TEM-15 beta-lactamase alleles, which constitute an adaptive path in

32 asmic events that lead to expression of beta-lactamase, an antibiotic-resistance determinant.

33 R164S, two adaptive mutations in TEM-1 beta-lactamase--an enzyme that endows antibiotics resistance.

34 re all ST106, and encoded for blaACT-15 beta-lactamase and fosfomycin resistance (fosA).

35 SpyTag was fused at the N terminus of beta-lactamase and SpyCatcher at the C terminus so that the p

36 Beta-lactamase and tetracycline resistance genes were the mos

37 Klebsiella pneumoniae that includes two beta-lactamase and two aminoglycoside resistance genes.

38 ergence and spread of extended-spectrum beta-lactamases and carbapenemases among common bacterial pat

39 clic beta-lactams are stable to metallo-beta-lactamases and have excellent P. aeruginosa activities d

40 it clinically relevant class A, C and D beta-lactamases and penicillin-binding proteins, resulting in

41 minants of beta-lactam resistance (e.g. beta-lactamase) and redox potential in Mtb.

42 oli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morganii.

43 rproducers), K1, other limited-spectrum beta-lactamases, and porin and efflux mutants.

44 ective against both serine- and metallo-beta-lactamases, and which could also have antimicrobial acti

45 beta-Lactamases are bacterial enzymes that hydrolyze beta-lac

46 beta-Lactamases are enzymes that confer resistance to beta-la

47 CTX-M beta-lactamases are one of the fastest growing extended-spect

48 ctive sites of DD-peptidases and serine beta-lactamases are very similar.

49 spergillus niger, and the TEM-family of beta-lactamase associated with antibiotic resistance.

50 bosomal protection proteins and Class A beta-lactamases being the most widely distributed resistance

51 sed by resistance, which is provided by beta-lactamases belonging to both metallo (MBL)- and serine (

52 microscopy with Eos-conjugated, ICS-located lactamase-beta indicated hypoxic ICS expansion with an u

53 The beta-Lactamase (BL) enzyme family is an important class of en

54 Herein, we report TEM-1 beta-lactamase (bla) as a single-protein reporter for hyperpo

55 dified to encode toxin with an in-frame beta-lactamase (Bla) fusion.

56 PRIMERS I, the 4 RMD platforms detected beta-lactamase (bla) genes and identified susceptibility or r

57 ere based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbapenemas

58 ere based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbapenemas

59 al with a second antigen fused to TEM-1 beta-lactamase (Bla).

60 scaping to hydrolysis by broad-spectrum beta-lactamase BlaC.

61 ulosis (Mtb) expresses a broad-spectrum beta-lactamase (BlaC) that mediates resistance to one of the

62 beta-Lactamases (BLs) able to hydrolyze beta-lactam antibioti

63 Production of beta-lactamases (BLs) is the most widespread resistance mecha

64 a bicyclic boronate inhibit L2 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from the

65 ows stability to most extended spectrum beta-lactamases, but is considered inactive against Pseudomon

66 For example, the secretion of beta-lactamase by individual bacteria provides passive resist

67 nucleophilic serine and zinc-dependent beta-lactamases by a mechanism involving mimicking of the com

68 t then that the active site of a serine beta-lactamase can catalyze hydrolysis of a beta-lactam while

69 most class A enzymes, most of the CTX-M beta-lactamases can be inhibited by the clinical inhibitors (

70 h the emphasis on the identification of beta-lactamases (carbapenemases OXA-48 and KPC in particular)

71 Metallo-beta-lactamases catalyze the hydrolysis of most beta-lactam a

72 by the polyketide synthase ClaG and the beta-lactamase ClaF.

73 FunFHMMer method can separate the known beta-lactamase classes and identify those positions likely to

74 Extended-spectrum beta-lactamase colonization was defined by the isolation of a

75 idime/avibactam are 2 novel beta-lactam/beta-lactamase combination antibiotics.

76 itive and specific for the detection of beta-lactamase compared to the blaZ PCR results, whereas the

77 TEM beta-lactamase confers bacteria with resistance to many antib

78 Here we report an artificial metallo-beta-lactamase, constructed via the self-assembly of a struct

79 genes that encode the extended-spectrum beta-lactamases CTX-M-2, CTX-M-14, and CTX-M-15.

80 by screening against nr, SEED, ARDB and beta-lactamase databases.

81 The catalytic efficiency of class D beta-lactamases depends critically on an unusual carboxylated

82 ution X-ray crystal structures of CTX-M beta-lactamase, directly visualizing protonation state change

83 n containing a highly conserved metallo-beta-lactamase domain, within which our swip-10 mutations are

84 ted a sample of 98 MRCAs of the metallo-beta-lactamases, each based on a different tree in a bootstra

85 roduct complexes for a wild-type serine beta-lactamase, elucidating the product release mechanism of

86 beta-Lactamases enable resistance to almost all beta-lactam a

87 were KPC (K. pneumoniae carbapenemases) beta-lactamases encoded by blaKPC2, blaKPC3, and blaKPC4, whi

88 s performed on all isolates to identify beta-lactamase-encoding genes.

89 member of the widely occurring metallo-beta-lactamase enzyme family.

90 antibiotics can be mediated by metallo-beta-lactamase enzymes (MBLs).

91 Through experiments using recombinant beta-lactamase enzymes and live bacterial species, these prob

92 Point mutations to beta-lactamase enzymes can greatly alter the level of resista

93 the catalytic mechanism of class A type beta-lactamase enzymes is still not well understood after dec

94 Bacteria use metallo-beta-lactamase enzymes to hydrolyse lactam rings found in man

95 ce homology with beta-lactamase/metallo-beta-lactamases (enzymes that provide resistance to a range o

96 actams is achieved by the production of beta-lactamases, enzymes that catalyze beta-lactam hydrolysis

97 pid rise in the number and diversity of beta-lactamases, enzymes that inactivate beta-lactams, a clas

98 ely identification of extended-spectrum beta-lactamase (ESBL) bacteremia can improve clinical outcome

99 for the treatment of extended-spectrum beta-lactamase (ESBL) bacteremia is controversial.

100 y was performed on 56 extended-spectrum-beta-lactamase (ESBL) E. coli isolates collected during 2 pre

101 f the fastest growing extended-spectrum beta-lactamase (ESBL) families found in Escherichia coli rend

102 as strains harboring extended-spectrum beta-lactamase (ESBL) genes, frequently use selective culture

103 terobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose sign

104 However, the rise of extended spectrum beta-lactamase (ESBL) producing bacteria has limited the use

105 clinical isolates for extended-spectrum beta-lactamase (ESBL) production (screen plus phenotypic conf

106 Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in the Democratic Republic o

107 ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenotype were assessed for th

108 vided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and CRE ca

109 y of studies reported extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and MDR Ac

110 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae generally

111 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae present an

112 robacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and susce

113 s aeruginosa and most extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.

114 haracterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and K. pneum

115 CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiel

116 Importance: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are highly a

117 Extended spectrum beta-lactamase (ESBL)-producing gram-negative bacilli are inc

118 r for infections with extended-spectrum beta-lactamase (ESBL)-producing organisms.

119 infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens is recognized globa

120 ne unreported case of extended-spectrum-beta-lactamase (ESBL)-producing Salmonella enterica serovar T

121 on (UTI) caused by an extended-spectrum beta-lactamase (ESBL)-producing, multidrug-resistant ST131 E.

122 ction of the CTX-M-15 extended spectrum beta-lactamase (ESBL).

123 ne resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

124 espectively, produced extended-spectrum beta-lactamases (ESBL).

125 laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiological and infection con

126 and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by farming and managerial p

127 of the genes encoding extended spectrum beta-lactamases (ESBLs) via conjugative plasmids is facilitat

128 Extended-spectrum beta-lactamases (ESBLs) were reported for 11.0% of Escherichi

129 solates that produced extended-spectrum beta-lactamases (ESBLs), AmpCs (including hyperproducers), K1

130 ants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, and broad-spectrum beta-l

131 onic acid synergy test, and the metallo-beta-lactamase Etest, had specificities of >90% for detecting

132 resence of high levels of contaminating beta-lactamases expressed by other clinically prevalent bacte

133 Some members of the class A beta-lactamase family are capable of conferring resistance to

134 veal that the robustness of the overall beta-lactamase fold coupled with the plasticity of an active

135 ance genes, including extended spectrum beta-lactamases, for which therapeutic options are scarce, an

136 against two clinically relevant class C beta-lactamases from Enterobacter spp. and Pseudomonas aerugi

137 ine beta-lactamase) but not L1 (metallo beta-lactamase) from the extensively drug resistant human pat

138 test the hypothesis of polyphyly further; if lactamase function has arisen twice independently, the m

139 the strength of evidence for or against MRCA lactamase function, we reconstructed a sample of 98 MRCA

140 g a lower bound of evidence for metallo-beta-lactamase functionality but not an upper bound.

141 ancestral proteins may have had metallo-beta-lactamase functionality with variation in sequence and s

142 els conform to our criteria for metallo-beta-lactamase functionality, suggesting that the ancestor wa

143 Finally, we used our beta-lactamase FunFams and ASSP profiles to detect 4 novel Cl

144 SrgE with beta-lactamase fused to residue 40, 100, 150, or 300 was inde

145 slocated into host cells, but SrgE with beta-lactamase fused to residue 400 or 488 was not expressed,

146 roducing a fusion protein consisting of beta-lactamase fused to the T4SS-translocated effector RalF,

147 ression of a gene island-borne putative beta-lactamase gene was observed following piperacillin-tazob

148 urrounding the active site of the TEM-1 beta-lactamase gene.

149 (bla CMY-42) and two extended-spectrum beta-lactamase genes (bla CTX-M-15 and bla SHV-12).

150 m-negative bacteria (GNB) are numerous; beta-lactamase genes carried on mobile genetic elements are a

151 itude reductions in effluent-associated beta-lactamase genes in effluent-saturated soils, suggesting

152 e molecularly characterized to identify beta-lactamase genes.

153 lactams have led to the conclusion that beta-lactamases have evolved from a DD-peptidase ancestor.

154 llin, and cefazolin, are protected from beta-lactamase hydrolysis via the formation of unique ion-pai

155 ional properties of the Bacillus cereus beta-lactamase II in the presence of chemical denaturants usi

156 of inhibitors for NDM-1 and two related beta-lactamases, IMP-1 and VIM-2, was identified.

157 f WhiB4 in coordinating the activity of beta-lactamase in a redox-dependent manner to tolerate AG.

158 nonoutbreak spread of New Delhi metallo-beta-lactamase in diverse Enterobacteriaceae species.

159 TEM-1 is a prevalent plasmid-encoded beta-lactamase in Gram-negative bacteria that efficiently cat

160 es were shown to activate expression of beta-lactamase in the absence of any beta-lactam antibiotic,

161 on of carbapenemases, including metallo-beta-lactamases in active bacterial pathogens.

162 ometry (LC-MS/MS) was applied to detect beta-lactamases in clinical Acinetobacter baumannii isolates.

163 olomycin also strongly inhibits metallo-beta-lactamases in vitro, major contributors to clinical carb

164 ype), 40 isolates that produced metallo-beta-lactamases (including NDM-1, GIM-1, SPM-1, IMP-1, -2, -7

165 ues able to inhibit clinically-relevant beta-lactamases, including AmpC, Extended-Spectrum BLs (ESBL)

166 aureus and Escherichia coli expressing beta-lactamases, infection was cleared when treated with anti

167 ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem alte

168 ibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the clinic

169 Resistance to the novel beta-lactam/beta-lactamase inhibitor combination ceftazidime-avibactam (C

170 s should not be extended to beta-lactam/beta-lactamase inhibitor combinations in development, as limi

171 h respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidime/avi

172 e 2 new second-generation cephalosporin/beta-lactamase inhibitor combinations.

173 the use of next-generation beta-lactam-beta-lactamase inhibitor combinations.

174 the final deprotection/isolation of the beta-lactamase inhibitor MK-7655 as a part of its manufacturi

175 bacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generation c

176 such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evaluated for the treatme

177 ctericidal activity in combination with beta-lactamase inhibitor, clavulanate (Clav).

178 dent upon or enhanced by clavulanate, a beta-lactamase inhibitor.

179 are unaffected by clinically available beta-lactamase inhibitors (betaLIs).

180 .15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.24-2.5

181 ated to discover a new series of serine beta-lactamase inhibitors containing a boronic acid pharmacop

182 drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstream in

183 Although several new beta-lactamase inhibitors have been approved or are in clinic

184 hereas newer drug classes include novel beta-lactamase inhibitors in combination with new or approved

185 cterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinically re

186 A multiligand set of boronic acid (BA) beta-lactamase inhibitors was obtained using covalent molecul

187 combinations of penicillins, including beta-lactamase inhibitors) and two had a known interaction in

188 ding green fluorescent proteins (GFPs), beta-lactamase inhibitors, and nuclear receptors, and we obse

189 o guide the creation of two novel short beta-lactamase inhibitors, here named dBLIP-1 and -2, with le

190 vibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence against ant

191 osporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains and ca

192 nam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like and bi

193 nt one of the most promising classes of beta-lactamase inhibitors.

194 m antibiotics in a manner distinct from beta-lactamase inhibitors.

195 anism distinct from that of traditional beta-lactamase inhibitors.

196 eal time the catalytic activity of TEM1-beta-lactamase inside living cells and compared the values to

197 In particular, derepression of the AmpC beta-lactamase is a common mechanism of beta-lactam resistanc

198 nducible expression of chromosomal AmpC beta-lactamase is a major cause of beta-lactam antibiotic res

199 The designed metallo-beta-lactamase is functional in the Escherichia coli periplas

200 The catalytic mechanism of class A beta-lactamases is often debated due in part to the large num

201 id (BZB), a nanomolar inhibitor of AmpC beta-lactamase (K i = 27 nM), we have identified and characte

202 Metallo-beta-lactamases (MbetaLs) are the main mechanism of resistanc

203 jor health threat by expressing metallo-beta-lactamases (MbetaLs), enzymes able to hydrolyse these li

204 mono-iron binding member of the metallo-beta-lactamase (MBL) fold superfamily.

205 otif related to the prokaryotic metallo-beta-lactamase (MBL) fold.

206 -2 and IMP-18, and 7 carried no metallo-beta-lactamase (MBL) gene.

207 Metallo-beta-lactamase (MBL) inhibitors can restore the function of c

208 The metallo-beta-lactamase (MBL) is a candidate protein family that inclu

209 emergence and global spread of metallo-beta-lactamase (MBL) mediated resistance, specifically New De

210 and OXA-type carbapenemases and metallo-beta-lactamases (MBL).

211 Metallo-beta-lactamases (MBLs) hydrolyze almost all beta-lactam antib

212 -lactam antibiotics mediated by metallo-beta-lactamases (MBLs) is a growing problem.

213 PADs) that can test for the presence of beta-lactamase-mediated resistance.

214 d that it shared sequence homology with beta-lactamase/metallo-beta-lactamases (enzymes that provide

215 High activity against extended-spectrum beta-lactamase, methicillin-resistant S. aureus, and carbapen

216 temperatures using a library of random beta-lactamase mutants containing these noncanonical amino ac

217 e (CRE) producing the New Delhi metallo-beta-lactamase (NDM) are rare in the United States, but have

218 New Delhi metallo-beta-lactamase (NDM) represents a serious challenge for treat

219 The New Delhi metallo-beta-lactamase (NDM-1) is involved in the emerging antibiotic

220 However, the emergence and spread of beta-lactamase-negative ampicillin-resistant strains in many

221 iscriminate between clinically-relevant beta-lactamases on the basis of their inhibition profile.

222 Previous use of beta-lactam/beta-lactamase or carbapenems and recent hospitalization were

223 eviously unrecognized extended-spectrum beta-lactamase or plasmid AmpC targets were detected and conf

224 Furthermore, in contrast to metallo-beta-lactamases or Klebsiella pneumoniae carbapenemases (KPC)

225 e between ESBL and non-ESBL TEM and SHV beta-lactamases or to specify CTX-M genes by group.

226 opment of new inhibitors of the class D beta-lactamase oxacillinase-48 (OXA-48) through surface plasm

227 10-site library (1,536 variants) of P99 beta-lactamase (P99betaL), a component of ADEPT cancer therap

228 this clinically important ESBL-type class A lactamase permits us to approach the challenge of inhibi

229 All isolates were beta-lactamase positive and were resistant to penicillin, tet

230 rior activity against extended spectrum beta lactamase producers, despite diminished activity against

231 Pseudomonas, and 10% extended-spectrum beta-lactamase-producing bacteria, without evidence of target

232 t on the detection of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in clini

233 re rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), compare

234 ections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E).

235 inal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and may

236 Extended-spectrum beta-lactamase-producing Enterobacteriaceae are difficult-to-

237 specificity of prior extended-spectrum beta-lactamase-producing Enterobacteriaceae colonization as a

238 dent risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae colonization, and

239 veillance culture for extended-spectrum beta-lactamase-producing Enterobacteriaceae detection was rou

240 Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae digestive coloniz

241 digestive tract with extended-spectrum beta-lactamase-producing Enterobacteriaceae during ICU-hospit

242 ation of at least one extended-spectrum beta-lactamase-producing Enterobacteriaceae from rectal swab

243 red colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in previously non

244 likely to develop an extended-spectrum beta-lactamase-producing Enterobacteriaceae infection (risk r

245 to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteriaceae infection were 95

246 ion as a predictor of extended-spectrum beta-lactamase-producing Enterobacteriaceae involvement in ve

247 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteriaceae outbreaks or data

248 disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteriaceae phenotypic confir

249 infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae predominated.

250 ) were colonized with extended-spectrum beta-lactamase-producing Enterobacteriaceae prior to the deve

251 U acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae ranged from 5% to

252 rest of screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae rectal carriage a

253 y higher frequency of extended-spectrum beta-lactamase-producing Enterobacteriaceae subsequent infect

254 for human exposure to extended-spectrum beta-lactamase-producing Enterobacteriaceae, methicillin-resi

255 being colonized with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

256 d pneumonia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae; of whom, 17 were

257 ized or infected with extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC).

258 ants of the spread of extended-spectrum beta-lactamase-producing Escherichia coli (ESBLEC) in the com

259 aureus) and ESBL-EC (extended-spectrum beta-lactamase-producing Escherichia coli) results in a disti

260 Escherichia coli, and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Salmonella

261 intervention cases of extended-spectrum beta-lactamase-producing organisms (P = 0.049) but not overal

262 infections caused by extended-spectrum beta-lactamase-producing organisms, AmpC beta-lactamase-produ

263 eta-lactamase-producing organisms, AmpC beta-lactamase-producing organisms, carbapenem-resistant Ente

264 a high prevalence of extended-spectrum beta-lactamase-producing organisms.

265 tams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12), and quinolones (plasmi

266 -resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapenem-resistant Enterobact

267 Combined extended-spectrum beta-lactamase production (blaTEM-1 gene) and azithromycin re

268 one edge and nitrocefin-based tests for beta-lactamase production in Staphylococcus aureus were 64.5%

269 beta-lactamase production is the predominant mechanism of res

270 Artemis is a member of the metallo-beta-lactamase protein family of nucleases.

271 The correlation of the detection of beta-lactamase proteins (rather than PCR detection of the cor

272 s with genes specifying homologs of a fungal lactamase (renamed prokaryotic 5-oxoprolinase A, pxpA) a

273 d proteolysis, one-dimensional NMR, and beta-lactamase reporter assays on eukaryotic cells, we show t

274 nts is the antioxidant response element beta lactamase reporter gene assay (ARE-bla), which identifie

275 Beta-lactamases represent the main bacterial mechanism of res

276 drug groups having known interactions (beta-lactamase-resistant penicillins [dicloxacillin] and carb

277 arks the first preparation of a metallo-beta-lactamase selectively substituted with a paramagnetic me

278 a coli cells carrying New Delhi metallo-beta-lactamase subclass 1 (NDM-1) can be monitored in real ti

279 to both metallo (MBL)- and serine (SBL)-beta-lactamase subfamilies.

280 , avibactam does not inactivate metallo-beta-lactamases such as New Delhi metallo-beta-lactamases.

281 (IntS11), which belongs to the metallo-beta-lactamase superfamily and is a paralog of CPSF-73, the e

282 Salmonella enterica subsp. arizonae The beta-lactamase TEM-1 reporter system showed that SeoC is tran

283 nicillin disk diffusion test, and three beta-lactamase tests, including the cefoxitin-induced nitroce

284 CphA is a Zn(2+)-dependent metallo-beta-lactamase that efficiently hydrolyzes only carbapenem an

285 carbapenemase (KPC) production or other beta-lactamases that hydrolyze carbapenems.

286 lows us to propose a grouping of serine beta-lactamases that more consistently captures and rationali

287 that is hydrolyzed by the enzyme BlaC (beta-lactamase) that is naturally expressed by M. tuberculosi

288 Among the reads characterized as beta-lactamases, the carbapenemase blaOXA was dominant in mos

289 Although they are grouped in class A beta-lactamases, the CTX-M family possesses low sequence iden

290 We focused on Class A beta-lactamases, the most highly populated and clinically rel

291 Although developed for the serine beta-lactamases they could be used to classify and analyse an

292 ation reporter was engineered by fusing beta-lactamase to the N terminus of TeNT [betalac-TeNT(RY)] t

293 similarities, why was it necessary for beta-lactamases to evolve at all?

294 encoding the emerging New Delhi metallo-beta-lactamase, using label-free electrochemical impedance sp

295 We assayed a TEM-1 beta-lactamase variant and levoglucosan kinase (LGK) using ye

296 C), and Verona integron-encoded metallo-beta-lactamase (VIM) were the most common carbapenemases foun

297 ant MBL Verona integron-encoded metallo-beta-lactamase (VIM-2).

298 the plasticity of the interface of TEM1 beta-lactamase with its protein inhibitor BLIP by low-stringe

299 Insidious coproduction of metallo-beta-lactamase with KPC-type carbapenemase has implications f

300 e complex of perdeuterated E166A Toho-1 beta-lactamase with the antibiotic cefotaxime.